


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06348 A2

(51) International Patent Classification ⁷ :	C08B	(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
(21) International Application Number:	PCT/US01/22501	
(22) International Filing Date:	18 July 2001 (18.07.2001)	
(25) Filing Language:	English	
(26) Publication Language:	English	
(30) Priority Data: 09/619,369	19 July 2000 (19.07.2000)	US
(71) Applicant: GENZYME CORPORATION [US/US]; One Kendall Square, Cambridge, MA 02139 (US).		
(72) Inventors: MILLER, Robert, J.; 59 Fairway Drive, Halifax, MA 02338 (US). SHIEDLIN, Aviva; 80 Francis Street, Brookline, MA 02446 (US).		
(74) Agent: COBERT, Robert, J.; 15 Pleasant Street Connec- tor, P.O. Box 9322, Framingham, MA 01701-9322 (US).		

Published:— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/06348 A2

(54) Title: MOLECULAR WEIGHT REDUCTION OF POLYMER USING IRRADIATION TREATMENT

(57) Abstract: A method for reducing the molecular weight of polymer comprises subjecting a solid phase polymer to a dose of gamma irradiation sufficient to permit the desired molecular weight reduction to occur.

MOLECULAR WEIGHT REDUCTION OF POLYMER
USING IRRADIATION TREATMENT

5

BACKGROUND OF THE INVENTION

This invention relates to methods for the controlled molecular weight reduction of polymers using specific amounts of high-energy irradiation, such as gamma irradiation. The methods of this invention permit the direct reduction of the molecular weight of such polymers 10 to preselected lower molecular weight levels with low polydispersity. Polymers which are particularly suitable for use in the present invention include the polyanionic polysaccharides, and more particularly hyaluronic acid ("HA") and carboxymethyl cellulose ("CMC").

Hyaluronic acid is a linear long-chain polysaccharide comprising repeating D-glucuronate and *N*-acetylglucosamine disaccharide units. Hyaluronic acid is not species 15 specific, and it may be obtained, for example, either by extraction from animal tissues, such as rooster combs and umbilical cords (Klein, J., & Meyer, F.A., 1983, *Biochem. & Biophys. Acta*, 755(3), 400-411), or by the removal of hyaluronic acid capsular material from bacterial species, e.g. *Streptococcus* (Van Brunt, J., 1986, *Biotechnology*, 4, 780-782). Hyaluronic acid from such sources exists as a mixture of different molecular weight species, and the overall 20 molecular weight of the product is expressed as a weight average molecular weight.

Hyaluronic acid has a variety of therapeutic applications, such as its use in ophthalmic surgery and for post-operative adhesion prevention, as well as having potential uses in a number of other areas. The key to many of the uses of hyaluronic acid lies in its hydrodynamic properties (Van Brunt, J., 1986, *Biotechnology*, 4, 780-782), which produces highly viscous 25 solutions at low concentrations. The viscosity of a hyaluronic acid solution is primarily dependent on the molecular weight, and the concentration of hyaluronic acid in solution.

The viscosity properties may be altered by the dilution of the polymer, but in many applications this approach is not acceptable because a specific concentration of the polymer is required for particular applications. Proposed strategies to produce hyaluronic acid having a 30 variety of preselected molecular weights include the selection of bacterial mutants capable of producing the desired hyaluronic acid molecular weight range, or the alteration of the physiological conditions during growth of a bacterium to enhance the production of a particular molecular weight range. However, neither of these techniques provides both the range and

diversity of molecular weight species required for specific applications due to the inherent limitations of these methods.

Alternatively, the reduction of high molecular weight hyaluronic acid to moieties of lower molecular weight may be achieved by enzymatic, chemical or physical means. Enzymatic methods of degrading hyaluronic acid are known, (Hamai, A., et al, 1989, *Agric. Biol. Chem.*, 53 (8), 2163-2168), but are relatively uncontrollable and tend to broaden the hyaluronic acid molecular weight distribution and therefore increase the polydispersity of the material. This makes the material particularly unsuitable for certain applications where highly defined molecular weight ranges are required. Chemical methods (Harris, M. J., et al, 1972, *JACS*, 94, 7570-7572), suffer similar problems and, moreover, may result in residual concentrations of the reacting chemicals remaining in a therapeutic product. Fractionation of hyaluronic acid into defined molecular weight species is feasible (Armand, G., & Reyes, M., 1983, *Biochem. & Biophys. Res. Comm.*, 112(1), 168-175), but this is a complex operation which is not easily controllable in large scale manufacturing operations.

U.S. Patent No. 5,491,227 describes a method for the molecular weight reduction of polysaccharides, such as hyaluronic acid, carboxymethyl cellulose and guar gum, by subjecting the polymers to pressure homogenization in a single pass through the device at pressures ranging from 10 Mpa to 25 Mpa. The hyaluronic acid product obtained as a result of the pressure homogenization has an average molecular weight of from about 1.2 to about 1.5×10^6 D, based upon an initial molecular weight of 1×10^7 D to 2×10^7 D. One potential shortcoming of this method is that it requires the polymer, in this case hyaluronic acid, to be processed in the solution phase. This requires the additional processing step of solidification and drying of the polymer so if, as is typically the case, a powdered product is desired. In addition, some polymers may not be amenable to being readily solubilized, and since this method requires a rather precise measurement of apparent viscosities, this can present processing problems.

The use of irradiation, such as gamma irradiation, to sterilize polymers and non-polymeric materials is known. It is also known that certain types of irradiation can be used to initiate polymerization reactions in certain polymers, and for the addition or substitution of certain pendant groups onto a polymer chain.

European Patent Application No. 269937 describes a process for the controlled preparation of low molecular weight glucosaminoglycans by treating the corresponding high molecular weight glucosaminoglycans with rectilinear gamma radiation at doses within the

range of 2.5 to 20 Mrad. The glucosaminoglycans which can be used in this process include heparin, chondroitin sulphate, keratan sulphate and hyaluronic acid, with heparin being the preferred glucosaminoglycan. The gamma radiation is supplied in successive irradiation stages, 5 followed by intervening cooling steps to prevent alteration of the molecular structure of the heparin. The reference is directed to low molecular weight heparin molecules that are reduced to fragments which are claimed to still possess biological activity.

It will be appreciated that it would be desirable to develop an improved process for the molecular weight reduction of high molecular weight polymers, such as hyaluronic acid and 10 carboxymethyl cellulose, to preselected lower values without the necessity of additional purification or other processing steps required in conventional approaches.

SUMMARY OF THE INVENTION

The present invention features a method for the reduction in the molecular weight of 15 high molecular weight polymers to substantially lower, preselected levels. The method of this invention comprises subjecting the high molecular weight polymer to a dose of irradiation sufficient to achieve the desired degree of molecular weight reduction. The present method is applied to the polymer in the solid phase, thereby eliminating the necessity of preparing a polymer solution. The use of polymer solutions requires a solubility step which is difficult to 20 perform for some polymers because of their limited solubility and/or the high viscosity of the solutions. The present method also avoids the expense and trouble of solidifying the polymer after the proper molecular weight has been achieved. Using the method of this invention, the molecular weight of polymers can be reduced directly in a controlled and reproducible manner, without the use of chemicals or enzymes that must be subsequently neutralized or removed.

25 The type and dosage of the irradiation that can be employed in the practice of this invention will vary depending on the type of polymer treated, the degree of molecular weight reduction desired, and the form of the polymer, i.e. whether the polymer is in the form of a salt. The preferred type of irradiation is gamma irradiation, although other types of irradiation, including heat sources, such as microwave irradiation, can also be used. Typically, the dosage 30 of irradiation used will vary from about 1 kGy to about 120 kGy.

In one embodiment, the polymer which can be treated according to the method of this invention is a polysaccharide polymer, preferably hyaluronic acid with an initial molecular

weight in the range of from about 3,000 kdaltons to about 1,000 kdaltons. In another embodiment, the polysaccharide polymer is carboxymethyl cellulose with an initial molecular weight in the range of from about 300 kdaltons to about 100 kdaltons.

5 The process of this invention does not require the use of additional processing steps in order to avoid structural changes to the polymer, or to remove impurities which may have been introduced into the polymer preparation as a direct result of the polymer processing.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention 10 pertains. Although any method and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder, including published patent applications, and issued or granted patents, are incorporated by reference herein. Unless mentioned otherwise, the techniques employed or contemplated herein are standard 15 methodologies well known to one of ordinary skill in the art. The materials, methods and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1 is a graph illustrating the decrease in molecular weight of four (4) samples of a hyaluronic acid preparation after exposure to gamma irradiation.

Figure 2 is a graph illustrating the decrease in molecular weight of four (4) samples of a hyaluronic acid preparation as a function of the log of gamma irradiation dose.

25 Figure 3 is a graph illustrating the decrease in molecular weight of two (2) samples of a preparation of a carboxymethyl cellulose preparation after exposure to gamma irradiation.

Figure 4 is a graph illustrating the decrease in molecular weight of two (2) samples of a carboxymethyl cellulose preparation as a function of the log of gamma irradiation dose.

Figure 5 is an FTIR spectrum of a hyaluronic acid powder sample before and after treatment with 90 kGy of gamma irradiation.

30 Figure 6 is an FTIR spectrum of a carboxymethyl cellulose powder sample before and after treatment with 90 kGy of gamma irradiation.

DETAILED DESCRIPTION

The present invention provides a method for the molecular weight reduction of high molecular weight polymers to lower molecular weight polymers based on the discovery that the 5 irradiation dose can be correlated with precision to the final molecular weight of the polymer.

As used herein, the term "high molecular weight" will depend on the type of polymer used in the method, but will generally denote molecular weights in excess of about 100 kdaltons. A "high molecular weight" hyaluronic acid polymer will typically have a molecular weight in the range of from about 1,000 kdaltons to about 3,000 kdaltons. A "high molecular 10 weight" carboxymethyl cellulose polymer, in contrast, will typically have a molecular weight in the range of from about 100 kdaltons to about 300 kdaltons.

The type and amount of irradiation used is dependent on the particular polymer species which is processed according to the invention. The method of this invention is applicable to a wide variety of polymers, but it is particularly applicable to the polyanionic polysaccharides, 15 and most preferably to hyaluronic acid and carboxymethyl cellulose. As used herein, and unless otherwise indicated, the term "polyanionic polysaccharide" denotes a polysaccharide containing more than one negatively charged group, e.g., carboxyl groups at pH values above about pH 4.0. This includes hyaluronic acid ("HA"), any of its hyaluronate salts, including, for example, sodium hyaluronate (the sodium salt), potassium hyaluronate, magnesium hyaluronate, and 20 calcium hyaluronate, carboxymethylcellulose ("CMC"), and mixtures of hyaluronic acid and carboxymethylcellulose ("HA/CMC").

The polymer treated according to this invention is in the solid phase prior to and during treatment. The term "solid phase" includes powders, granules, flakes, particles, and the like, but excluding bulk solid forms such as bars, pellets, extruded shapes, and the like. The irradiation is 25 applied directly to the polymer in the solid phase, and no solution is required. This avoids the necessity of using cooling steps between irradiation treatments, and the necessity of purifying the polymer after treatment.

The effect of irradiation dose on product molecular weight for hyaluronic acid and carboxymethyl cellulose are shown in Figures 1, 2, 3 and 4, respectively. These Figures show 30 that molecular weights decrease linearly with the natural log of the dose of gamma irradiation. The starting molecular weight of the polymer influences the final molecular weight only at low doses (i.e. up to 30kGy), as shown in these Figures. This characteristic permits the calculation

of the precise amount of irradiation required in order to achieve a preselected final polymer molecular weight based on the known starting molecular weight of the polymer. This type of linear relationship can be developed for a wide variety of polymers of interest, including
5 hyaluronic acid and carboxymethyl cellulose.

The following examples of this aspect of the invention are given by way of illustration and are not intended to limit the invention except as set forth in the appended claims. As shown in the examples, weight average molecular weights ("MW") and polydispersity index ("PI") were measured using Size Exclusion Chromatography coupled to Multiangle Laser Light
10 Scattering ("SEC/MALLS"). PI is defined as the ratio between weight average molecular weight and number average molecular weight (M_w/M_n), and is an accepted measure of the breadth of the molecular weight distribution.

EXAMPLE 1

15 This example illustrates the effect of gamma irradiation on hyaluronic acid powder. Four (4) lots (Lots A, B, C and D) of medical grade hyaluronic acid powder were subjected to successive doses of gamma irradiation as shown in Table 1 below and in Figures 1 and 2. Table 1 shows the effects of the irradiation treatment on the weight average molecular weight (MW) and (PI) of the hyaluronic acid tested. Figures 1 and 2 illustrate the dependency of the
20 molecular weight on irradiation treatment. The correlation coefficient from linear regression analysis of (R^2) of 0.99 is also shown. This data indicates that irradiation dose can be used to predict final molecular weight.

Table I

	Lot A	Lot A	Lot B	Lot B	Lot C	Lot C	Lot D	Lot D
<u>Energy</u>	<u>HA</u>	<u>PI</u>	<u>HA</u>	<u>PI</u>	<u>HA MW</u>	<u>PI</u>	<u>HA MW</u>	<u>PI</u>
<u>Dose</u>	<u>MW</u>	<u>(Mw/Mn)</u>	<u>MW</u>	<u>(Mw/Mn)</u>	<u>[kdaltons]</u>	<u>(Mw/Mn)</u>	<u>[kdaltons]</u>	<u>(Mw/Mn)</u>
<u>[kGy]</u>	<u>[kdaltons]</u>		<u>[kdaltons]</u>					
0	1640	1.1	1800	1.2	1100	1.3	2100	1.1
2.0	420	1.2	430	1.2	340	1.2		
4.1	260	1.2	290	1.2	210	1.2		
6.4	180	1.2	190	1.2	150	1.2		
7.8	170	1.2	180	1.1	130	1.1		
8.9							260	1.2
11.0	130	1.2	150	1.1	130	1.1		
11.9							180	1.1
12.9	150	1.2	130	1.1	110	1.1		
14.3							150	1.1
14.9	110	1.1	110	1.1	92	1.1		
17.1	100	1.1	100	1.1	81	1.1		
18.1	80	1.2	90	1.1	75	1.1		
20.4							120	1.1
26.2							90	1.1
30.0	78							
60.0	44							
90.0	29							

EXAMPLE 2

This example illustrates that the technique is predictable, reproducible, and controllable. One lot of medical grade hyaluronic acid powder was subjected to the same dose of gamma 5 irradiation on three different occasions. The MW and PI of the hyaluronic acid were found to be identical in all three cases.

Table 2

<u>Energy Dose</u> [kGy]	<u>HA MW</u> [kdaltons]	<u>PI</u> (Mw/Mn)
5.5-6.4	190	1.1
5.6-6.4	190	1.1
6.3-6.4	180	1.2

EXAMPLE 3

10 This example illustrates the absence of a side reaction from the high-energy irradiation of hyaluronic acid such as the deacylation of the acetyl groups in *N*-acetylglucosamine.

Residual free amine was measured in aqueous solutions of various hyaluronic acid samples by derivatization of any free amine with fluorescamine. The relative fluorescence of the depolymerized samples was compared to the starting hyaluronic acid, and the results are 15 shown in Table 3 below.

Table 3

<u>Energy Dose [kGy]</u>	<u>% Free Amines [moles]</u>
0	0.013
2	0.016
7.8	0.024
15	0.033
18.1	0.037
30	0.054

5 A significant increase in the relative fluorescence in the depolymerized hyaluronic acid samples would be indicative of an increased free amine content of the samples. As shown in Table 3, the increase in the free amine content is negligible.

EXAMPLE 4

10 This example illustrates the effect of gamma irradiation on carboxymethyl cellulose powder.

Two (2) lots (Lots A and B) of commercial grade carboxymethyl cellulose powder (Aqualon), with different molecular weights, were subjected to successive doses of high energy irradiation as shown in Table 4 below and Figures 3 and 4.

15 Table 4 shows the effects of the irradiation treatment on the average molecular weight of the carboxymethyl cellulose tested. Figures 3 and 4 illustrate the dependency of molecular weight and irradiation. A correlation coefficient from linear regression analysis of (R^2) of 0.99 is shown. This indicates that irradiation dose can be used to predict final molecular weight

Table 4

	Lot A	Lot A	Lot B	Lot B
<u>Energy Dose</u>	<u>CMC MW</u>	<u>PI</u>	<u>CMC MW</u>	<u>PI</u>
<u>[kGy]</u>	<u>[kdaltons]</u>	<u>(Mw/Mn)</u>	<u>[kdaltons]</u>	<u>(Mw/Mn)</u>
0	110	2	250	2
30	63	2.2	95	2
60	46	2.2	59	2.5
90	37	2.3	46	2.3

EXAMPLE 5

5 This example is intended to determine whether there have been any gross changes in the functional groups, such as intact amide and carboxyl groups, which are contained on the hyaluronic acid and carboxymethyl cellulose molecules.

10 Transmission FT/IR spectra was used to identify and monitor chemical changes. Spectra of carbohydrates before and after irradiation treatment were taken and compared. The results are shown in Figures 5 and 6 for hyaluronic acid and carboxymethyl cellulose, respectively. There are no gross chemical changes in either hyaluronic acid or carboxymethyl cellulose after gamma irradiation as compared to the non-irradiated polymer.


15 From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. As one skilled in the art will appreciate, the pharmaceutical preparations of the invention can be made using protocols which are within the method of the invention yet are different in particulars from those described herein.

What is claimed is:

CLAIMS

1. A method for the controlled molecular weight reduction of a high molecular weight polymer comprising the steps of:
 - 5 selecting a polymer having an initial molecular weight which exceeds a preselected lower molecular weight, said polymer being in the solid phase,
 - subjecting the polymer to irradiation in a dosage amount sufficient to reduce the molecular weight of the polymer to the preselected lower level, and
 - 10 obtaining a purified polymer product having the desired molecular weight.
2. The method of claim 1 wherein the polymer is in powder form.
3. The method of claim 1 wherein the polymer is a polysaccharide polymer.
- 15 4. The method of claim 3 wherein the polymer is hyaluronic acid.
5. The method of claim 3 wherein the polymer is carboxymethyl cellulose.
- 20 6. The method of claim 1 wherein the molecular structure of the polymer is intact after molecular weight reduction.
7. The method of claim 2 wherein a purified polymer is obtained without the use of additional purification treatment.
- 25 8. The method of claim 1 wherein the type of irradiation used is gamma irradiation.
9. The method of claim 8 wherein the dosage level of gamma irradiation is from about 1 kGy to about 120 kGy.

1/6

**Figure 1**




Figure 2

3/6




Figure 3

4/6





Figure 4

5/6

FT/IR Spectra - 1800 kDa vs. 22 kDa HA**Figure 5**

6/6




Figure 6

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06348 A3

(51) International Patent Classification⁷: C08J 3/28, C08B 37/00, 37/08, 11/12, 11/20

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/22501

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 18 July 2001 (18.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/619,369 19 July 2000 (19.07.2000) US

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(71) Applicant: GENZYME CORPORATION [US/US]:
One Kendall Square, Cambridge, MA 02139 (US).

(72) Inventors: MILLER, Robert, J.: 59 Fairway Drive, Halifax, MA 02338 (US). SHIEDLIN, Aviva: 80 Francis Street, Brookline, MA 02446 (US).

(74) Agent: COBERT, Robert, J.: 15 Pleasant Street Connector, P.O. Box 9322, Framingham, MA 01701-9322 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

(88) Date of publication of the international search report: 16 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/06348 A3

(54) Title: MOLECULAR WEIGHT REDUCTION OF POLYMER USING IRRADIATION TREATMENT

(57) Abstract: A method for reducing the molecular weight of polymer comprises subjecting a solid phase polymer to a dose of gamma irradiation sufficient to permit the desired molecular weight reduction to occur.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/22501

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C08J3/28	C08B37/00	C08B37/08	C08B11/12	C08B11/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C08J C08B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EP0-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 249 814 A (THE DOW CHEMICAL COMPANY) 13 October 1971 (1971-10-13) the whole document ---	1-3,5-9
X	DATABASE WPI Week 199514 Derwent Publications Ltd., London, GB; AN 1995-101801 XP002191936 "Antibacterial substance having high antibacterial activity - obtd. by irradiating polysaccharide with ionising radiation" & JP 07 025772 A (JAPAN ATOMIC ENERGY RES INST), 27 January 1995 (1995-01-27) abstract ---	1-3,6-9 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 March 2002

21/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Mazet, J-F

2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US.01/22501

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS; OHIO; US; KUME TAMIKAZU ET AL.: "Preparation of phytoalexin-inducing oligosaccharides by radiochemical degradation of polysaccharides." Database accession no. 128:295001 XP002191934 abstract & JP 10 101704 A (JAPAN ATOMIC ENERGY RESEARCH INSTITUTE) 21 April 1998 (1998-04-21) ---	1-3,6,7
X,P	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE; COLUMBUS; OHIO; US; FUJITA MITSUNARI ET AL.: "Medical goods containing dissolution-controlled irradiated hyaluronic acid gel." Database accession no. 133:213221 XP002191935 abstract & JP 2000 237294 A (DENKI KAGATU KOGYO K.K.) 5 September 2000 (2000-09-05) ---	1,3,4, 6-8
X	US 4 420 611 A (SCHEVE) 13 December 1983 (1983-12-13) column 2, line 5 - line 18; example 1 ---	1-3,5-9
X	EP 0 708 113 A (HOECHST AKTIENGESELLSCHAFT) 24 April 1996 (1996-04-24) claims ---	1-3,6-9
X	EP 0 269 937 A (MEDIOLANUM FARMACEUTICI SRL) 8 June 1988 (1988-06-08) cited in the application page 2, line 3 - line 9 page 2, line 36 - line 50 claims ---	1,3,4,6, 8
P,X	EP 1 050 544 A (KUHN MANFRED DR) 8 November 2000 (2000-11-08) abstract; claims; example 1 ---	1-3,6-9
X	DE 198 21 598 A (HENKEL KGAA) 18 November 1999 (1999-11-18) abstract; claims; examples 1,2 ---	1-3,6-9
X	WO 93 20952 A (THE GILETTE COMPANY) 28 October 1993 (1993-10-28) page 5, line 7 - line 20 page 5, line 30 - line 34; example 1 -----	1,2,6-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22501

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
GB 1249814	A	13-10-1971	DE SE	1928046 A1 361888 B	18-12-1969 19-11-1973
JP 07025772	A	27-01-1995	NONE		
JP 10101704	A	21-04-1998	NONE		
JP 2000237294	A	05-09-2000	NONE		
US 4420611	A	13-12-1983	BR CA DE FR JP JP JP NL	8301337 A 1216815 A1 3309465 A1 2523585 A1 1718724 C 4000081 B 58208301 A 8300939 A	29-11-1983 20-01-1987 29-09-1983 23-09-1983 14-12-1992 06-01-1992 05-12-1983 17-10-1983
EP 708113	A	24-04-1996	DE CA DE EP JP US US	4434280 A1 2159045 A1 59505079 D1 0708113 A1 8176201 A 5719274 A 5928709 A	28-03-1996 27-03-1996 25-03-1999 24-04-1996 09-07-1996 17-02-1998 27-07-1999
EP 269937	A	08-06-1988	IT AT AU AU CA DE DK EP FI GR JP JP JP NO PT US	1213384 B 60924 T 603622 B2 8160987 A 1305134 A1 3768074 D1 602387 A 0269937 A2 875185 A , B, 3001670 T3 1877327 C 5088881 B 63213502 A 874777 A 86191 A , B 4987222 A	20-12-1989 15-03-1991 22-11-1990 26-05-1988 14-07-1992 28-03-1991 15-09-1988 08-06-1988 25-05-1988 23-11-1992 07-10-1994 24-12-1993 06-09-1988 25-05-1988 01-12-1987 22-01-1991
EP 1050544	A	08-11-2000	DE EP	19920688 A1 1050544 A1	23-11-2000 08-11-2000
DE 19821598	A	18-11-1999	DE	19821598 A1	18-11-1999
WO 9320952	A	28-10-1993	US AT AU BR CA CN CZ DE DE DK	5263256 A 188145 T 4285593 A 9306258 A 2118236 A1 1079932 A , B 9402557 A3 69327460 D1 69327460 T2 640019 T3	23-11-1993 15-01-2000 18-11-1993 30-06-1998 28-10-1993 29-12-1993 18-10-1995 03-02-2000 13-07-2000 10-04-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/22501

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9320952	A	EG 19665 A	30-08-1995
		EP 0640019 A1	01-03-1995
		ES 2139659 T3	16-02-2000
		FI 944817 A	14-12-1994
		GR 3032436 T3	31-05-2000
		HU 75431 A2	28-05-1997
		JP 7505802 T	29-06-1995
		KR 251503 B1	15-04-2000
		MX 9302212 A1	01-10-1993
		NO 943896 A	08-12-1994
		NZ 252824 A	26-04-1996
		PL 173325 B1	27-02-1998
		PT 640019 T	30-06-2000
		RU 2107556 C1	27-03-1998
		TR 26693 A	15-05-1995
		WO 9320952 A1	28-10-1993
		ZA 9302654 A	22-10-1993